Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox injection for weight loss in obesity
NCT04274608Phase 3Unknown
- Sponsor
- Tan Tock Seng Hospital
- Start
- Jan 2020
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botulinum toxin type A in obesity (2 arms), sponsored by Tan Tock Seng Hospital. Primary endpoints: Weight loss at 1 year and Time to weight regain at 1 year. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04274608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274608.